Tonix Pharmaceuticals Holding Corp.
TNXP
$13.22
$1.2410.35%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 183.16% | 108.75% | 16.58% | -9.51% | -2.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 183.16% | 108.75% | 16.58% | -9.51% | -2.14% |
| Cost of Revenue | 67.34% | -10.57% | -12.09% | -2.82% | -43.19% |
| Gross Profit | 256.66% | 209.65% | 51.78% | -9.92% | 80.78% |
| SG&A Expenses | 183.29% | 128.96% | 233.48% | 115.97% | 8.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 161.94% | 114.17% | 97.85% | 47.29% | -22.45% |
| Operating Income | -158.73% | -114.80% | -112.59% | -54.13% | 24.81% |
| Income Before Tax | -138.84% | -112.19% | -125.22% | 64.11% | -12.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -138.84% | -112.19% | -125.22% | 64.11% | -12.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -138.84% | -112.19% | -125.22% | 64.11% | -12.65% |
| EBIT | -158.73% | -114.80% | -112.59% | -54.13% | 24.81% |
| EBITDA | -163.36% | -117.42% | -124.19% | -59.35% | 23.50% |
| EPS Basic | -3.28% | 59.29% | 84.18% | 99.80% | 99.47% |
| Normalized Basic EPS | -17.93% | 59.29% | 84.18% | 99.20% | 99.54% |
| EPS Diluted | -3.28% | 59.29% | 84.18% | 99.80% | 99.47% |
| Normalized Diluted EPS | -17.93% | 59.29% | 84.18% | 99.20% | 99.54% |
| Average Basic Shares Outstanding | 131.26% | 421.27% | 1,323.78% | 17,771.46% | 21,144.44% |
| Average Diluted Shares Outstanding | 131.26% | 421.27% | 1,323.78% | 17,771.46% | 21,144.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |